FDA Approves Teva Huntington's Drug

Source: FDA

Apr 04, 2017

The U.S. Food and Drug Administration has approved a Teva Pharmaceutical Industries drug, Austedo, for the treatment of chorea stemming from Huntington's disease.

According to Teva, the FDA approval was based on results from a late-stage study of Austedo in reducing chorea in patients with the degenerative disorder. The company also claims the approval was held up by regulators' desire for more blood studies.

The news, which according to Reuters analysts are forecasting annual sales up to $850 million by 2023, comes after a rocky time for Teva following its CEO stepping down.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments